Israeli health insurer curbs activities of drug representativesBMJ 1999; 319 doi: https://doi.org/10.1136/bmj.319.7221.1324c (Published 20 November 1999) Cite this as: BMJ 1999;319:1324
- Judy Siegel-Itzkovich
Israel's largest public health insurer has decided to restrict the activities of drug company representatives sent to its community clinics and hospitals.
Kupat Holim Clalit, which insures 60% of the population, said that it would bar entry to those representatives who disseminate “false and misleading information” about their products and violate the rules of medical ethics.
The organisation warned that it would file a personal complaint with the police against any representative caught violating these rules. In a letter to the heads of all its districts and hospitals, the head of the health fund's medical branch said …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial